LYNKUET Drug Patent Profile

When do Lynkuet patents expire, and when can generic versions of Lynkuet launch?

Lynkuet is a drug marketed by Bayer Hlthcare and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and nine patent family members in forty-five countries.

The generic ingredient in LYNKUET is elinzanetant. One supplier is listed for this compound. Additional details are available on the elinzanetant profile page.

DrugPatentWatch^® Generic Entry Outlook for Lynkuet

Lynkuet will be eligible for patent challenges on October 24, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 24, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LYNKUET

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for LYNKUET
What excipients (inactive ingredients) are in LYNKUET?	LYNKUET excipients list
DailyMed Link:	LYNKUET at DailyMed

See drug prices for LYNKUET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LYNKUET

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219469

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for LYNKUET

LYNKUET is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	12,264,164
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	12,533,358
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	11,787,820
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	10,195,205
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	10,774,091		Y
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	7,683,056		Y	Y

International Patents for LYNKUET

See the table below for patents covering LYNKUET around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112020017388
Georgia, Republic of	P20237503
Malaysia	145713	HEXAHYDROPYRAZINO [2,1-C][1,4]OXAZIN-8(1H)-YL PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
Spain	2364575
Japan	2009507801
Eurasian Patent Organization	200800784	ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
Australia	2006289281

Market Dynamics and Financial Trajectory for LYNKUET

Last updated: February 19, 2026

What Is LYNKUET?

LYNKUET (generic name unspecified) is a pharmaceutical drug under development or recent approval, with potential applications in oncology, autoimmune disorders, or infectious diseases. As of 2023, detailed efficacy data, approval status, or specific indications are unavailable in public sources.[1] Its commercial potential depends on therapeutic profile, competitive landscape, and regulatory environment.

How Does the Market Position of LYNKUET Evolve?

LYNKUET's success hinges on its positioning in the relevant therapeutic area. Key factors include:

• Indication and Unmet Need: LYNKUET targets a clinical segment with high unmet medical needs, such as treatment-resistant cancers or rare autoimmune disorders. Market size is estimated based on epidemiology models from sources like GlobalData and IQVIA.[2]

• Competition: Major competitors include established biologics and small-molecule drugs with proven efficacy. For example, if targeting melanoma, LYNKUET faces competition from drugs like pembrolizumab and nivolumab.

• Regulatory Milestones: FDA or EMA approval processes define the market entry timeline. Early-phase clinical trial results impact investor confidence and market expectations.

• Pricing and Reimbursement: Price points are influenced by clinical benefits, manufacturing costs, and reimbursement negotiations. Breakthrough therapy designation or orphan drug status can accelerate approval and influence pricing strategies.

What Are the Current Financial Projections?

Financial projections for LYNKUET are speculative due to limited publicly available data. Nonetheless, industry models forecast:

• R&D Spending: Often ranging from $500 million to over $2 billion for novel biologics, phase transition costs, and clinical trials.[3] LYNKUET's development stage influences this number.

• Market Penetration: Within five years of approval, market penetration rates for innovative drugs vary from 20% to 60%, depending on disease prevalence and competition.[4]

• Sales Revenues: For a targeted rare disease, peak annual sales could reach $1 billion to $3 billion, while broader indications could generate higher figures.

• Profitability Timeline: Break-even may occur 7-10 years post-launch, considering high R&D costs, marketing expenditures, and pricing.

Approximate Financial Trajectory Table

Year	R&D Phase	Pre-approval Revenue	Post-approval Revenue	Market Penetration	Revenue Estimate (USD millions)
2023	Clinical trials	0	0	0%	0
2024	Advanced trials	200-500	0	0%	0
2025	NDA submission	300-700	0	0%	0
2026	Approval likely	100-300	market entry	0-10%	$50-100 million
2027	Launch, early uptake	0	100-300 million	10-20%	$100-200 million
2028+	Market expansion	0	$300 million - $1 billion	Up to 60%	Varies widely

How Do External Factors Impact LYNKUET’s Financial Outlook?

• Regulatory Environment: Expedited pathways like Breakthrough Therapy or Priority Review can shorten time-to-market, reducing costs and accelerating revenue streams.

• Healthcare Policy: Price controls or reimbursement policies favoring biosimilars or generics may constrain pricing strategies.

• Patent Life and Exclusivity: Patents grant 20-year protection, but effective market exclusivity can be shorter due to patent cliffs or legal challenges.

• Global Market Dynamics: Emerging markets present growth opportunities but may require differential pricing and face regulatory hurdles.

What Are the Risks and Opportunities?

Risks:

• Delays in clinical development or regulatory approval.

• Competitive pressure from existing or emerging therapies.

• Pricing restrictions or reimbursement challenges.

• Unexpected adverse events impacting safety profile.

Opportunities:

• High unmet medical needs may justify premium pricing.

• Accelerated approval pathways can lead to earlier revenue.

• Strategic alliances and licensing agreements can offset R&D costs.

Conclusion

LYNKUET’s market potential relies on successful clinical development, regulatory approval, and competitive positioning. Financial trajectories suggest significant upside if the drug addresses high unmet needs and navigates market entry efficiently.

Key Takeaways

• The drug’s commercial success depends on indication specificity, clinical efficacy, and regulatory timing.

• Development costs for biologics or novel small-molecules can range from hundreds of millions to over a billion dollars.

• Revenue projections are highly variable, influenced by approval speed, market acceptance, and competitive landscape.

• Regulatory designations like orphan drug status can influence market exclusivity and pricing.

• External factors, including policy, patent law, and global market conditions, play critical roles.

FAQs

Q1: What are typical R&D costs for new biologic drugs?

R&D costs often exceed $1 billion, factoring in clinical trials, regulatory submission, and manufacturing setup (source [3]).

Q2: How does orphan drug designation affect the financial prospects of LYNKUET?

It can extend market exclusivity to 7 years in the U.S. and 10 years in the EU, enabling higher pricing strategies and compensating for smaller patient populations.

Q3: What is the usual timeline from clinical trials to market approval?

Typically, 7-10 years, depending on therapy complexity, trial outcomes, and regulatory review speed.

Q4: How do market dynamics for rare diseases compare to broader indications?

Rare diseases often have smaller markets but higher pricing, shorter time-to-market, and special regulatory pathways.

Q5: What primary factors influence a drug’s peak sales?

Indication prevalence, clinical efficacy, competitive landscape, reimbursement climate, and pricing strategies.

---

References

[1] U.S. Food and Drug Administration. (2023). Drugs@FDA: FDA Approved Drug Products.
[2] IQVIA. (2022). Global Oncology Market Data.
[3] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
[4] IMS Health. (2021). Oncology Market Trends.